Prostate Cancer Screening: What Can We Learn from Randomised Trials?

Overview

Journal Transl Androl Urol

Date 2018 Mar 30

PMID 29594015

Citations 1

Authors

Anssi Auvinen

Affiliations

Soon will be listed here.

Abstract

In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.

Citing Articles

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.

Booth N, Rissanen P, Tammela T, Kujala P, Stenman U, Taari K PLoS One. 2019; 14(11):e0224479.

PMID: 31689326 PMC: 6830755. DOI: 10.1371/journal.pone.0224479.

References

Veerus P, Hovi S, Fischer K, Rahu M, Hakama M, Hemminki E . Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. 2006; 55(2):162-73. DOI: 10.1016/j.maturitas.2006.01.012. View

Randazzo M, Muller A, Carlsson S, Eberli D, Huber A, Grobholz R . A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int. 2015; 117(4):576-83. PMC: 4955666. DOI: 10.1111/bju.13310. View

Wood L, Egger M, Gluud L, Schulz K, Juni P, Altman D . Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008; 336(7644):601-5. PMC: 2267990. DOI: 10.1136/bmj.39465.451748.AD. View

Concato J, Wells C, Horwitz R, Penson D, Fincke G, Berlowitz D . The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006; 166(1):38-43. DOI: 10.1001/archinte.166.1.38. View

Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O . 15-year followup of a population based prostate cancer screening study. J Urol. 2009; 181(4):1615-21. DOI: 10.1016/j.juro.2008.11.115. View

Kilpelainen T, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K . Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. J Urol. 2017; 198(1):50-57. DOI: 10.1016/j.juro.2017.01.048. View

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. PMC: 6027585. DOI: 10.1056/NEJMoa1113135. View

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttamies A . A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017; 32(6):521-527. DOI: 10.1007/s10654-017-0292-5. View

Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y . Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015; 16(16):1667-76. DOI: 10.1016/S1470-2045(15)00361-7. View

10.

Saarimaki L, Tammela T, Maattanen L, Taari K, Kujala P, Raitanen J . Family history in the Finnish Prostate Cancer Screening Trial. Int J Cancer. 2014; 136(9):2172-7. DOI: 10.1002/ijc.29243. View

11.

Castro E, Mikropoulos C, Bancroft E, Dadaev T, Goh C, Taylor N . The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist. 2016; 21(6):716-22. PMC: 4912360. DOI: 10.1634/theoncologist.2015-0336. View

12.

Nevalainen J, Stenman U, Tammela T, Roobol M, Carlsson S, Talala K . What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiol. 2016; 46:14-19. PMC: 5415347. DOI: 10.1016/j.canep.2016.11.005. View

13.

Tsodikov A, Gulati R, Heijnsdijk E, Pinsky P, Moss S, Qiu S . Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017; 167(7):449-455. PMC: 5734053. DOI: 10.7326/M16-2586. View

14.

Gulati R, Tsodikov A, Wever E, Mariotto A, Heijnsdijk E, Katcher J . The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control. 2012; 23(6):827-35. PMC: 3556907. DOI: 10.1007/s10552-012-9951-8. View

15.

Pashayan N, Pharoah P, Schleutker J, Talala K, Tammela T, Maattanen L . Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer. 2015; 113(7):1086-93. PMC: 4651137. DOI: 10.1038/bjc.2015.289. View

16.

Bryant R, Sjoberg D, Vickers A, Robinson M, Kumar R, Marsden L . Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015; 107(7). PMC: 4554254. DOI: 10.1093/jnci/djv095. View

17.

Parekh D, Punnen S, Sjoberg D, Asroff S, Bailen J, Cochran J . A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2014; 68(3):464-70. DOI: 10.1016/j.eururo.2014.10.021. View

18.

de Koning H, Gulati R, Moss S, Hugosson J, Pinsky P, Berg C . The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer. 2017; 124(6):1197-1206. PMC: 5839977. DOI: 10.1002/cncr.31178. View

19.

Moher D, Hopewell S, Schulz K, Montori V, Gotzsche P, Devereaux P . CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010; 63(8):e1-37. DOI: 10.1016/j.jclinepi.2010.03.004. View

20.

Harman N, Conroy E, Lewis S, Murray G, Norrie J, Sydes M . Exploring the role and function of trial steering committees: results of an expert panel meeting. Trials. 2015; 16:597. PMC: 4696246. DOI: 10.1186/s13063-015-1125-z. View